secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001193125-23-233934
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics starts Phase 3 trial for epetraborole in refractory MAC lung disease
--------------------------------------------------------------------------------

- Phase 2 enrollment completed with 80 patients; topline Phase 2 data expected summer 2024.
- Phase 3 part launched with over 100 sites in U.S., Japan, South Korea, Australia; plans to enroll ~230 patients.
- Epetraborole is an oral, once-daily drug; FDA granted Fast Track, QIDP, and orphan drug designations.
- No approved oral therapy currently exists for MAC lung disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523233934/0001193125-23-233934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523233934/d545132d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-233934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer